• Proceedings of the PSK Conference
• /
• 2003.04a
• /
• pp.244.1-244.1
• /
• 2003

Advances in understanding of pain and analgesia have been made. Over the past few years, we have designed and synthesized a series of VR agonists, based on the structures of 12-HPETE and capsaicin. the natural VR agonist. But for the development of analgesic drugs, these synthetic VR agonists had problems like burning sensation. hypothermia. etc. So our recent studoes have focused on designs and syntheses of VR antagonists based on the structure of capsaicin(natural VR agonist), and capsazepine(synthetic VR antagonist). (omitted)

• Korean Journal of Clinical Pharmacy
• /
• v.34 no.1
• /
• pp.1-20
• /
• 2024

This review examines the pivotal clinical trials that evaluated the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in the management of obesity. The reported findings underscore significant and sustained weight loss achieved with semaglutide in diverse patient groups, although gastrointestinal disorders occurred frequently, leading to therapy discontinuation. Overall, the studies demonstrated the potential of semaglutide as a therapeutic option not only for type 2 diabetes but also for obesity. The treatment landscape in obesity is evolving, as reflected in changing regulatory approvals and clinical guidelines, suggesting a paradigm shift toward personalized approaches in this chronic disease states to achieve optimal treatment outcomes for patients.

• Clinical and Experimental Pediatrics
• /
• v.51 no.6
• /
• pp.634-639
• /
• 2008

Purpose : There has been considerable disagreement regarding the most appropriate dosage of gonadotropin-releasing hormone agonist in cases of central precocious puberty. The aim of this study was to determine the appropriate dosage for suppression of the puberty in girls with central precocious or early puberty. Methods : Twenty-two girls with early puberty were randomly subjected to 3 types of dosages of leuprolide acetate for at least 6 months. The number of cases in groups 1, 2, and 3 were 7, 7, and 8, and dosages were 70, 90, and $110{\mu}g/kg/-month$, respectively. Height, weight, bone age, Tanner stage of breast development, and serum levels of LH, FSH, estradiol, and progesterone were measured before treatment and after 6 months of treatment. The number of cases of puberty suppression was compared using a modified puberty suppression score with a nonparametric chi-square test. Results : There were no significant differences of chronologic and bone ages among the groups. There was a significant decrease in height SDS gain after 6 months in group 3 (P<0.05) compared with groups 1 and 2. Serum levels of LH, FSH, estradiol and progesterone were all significantly decreased after treatment in all 3 groups (P<0.05). The number of cases of puberty suppression in each group were 4 (57%), 5 (71%), and 8 (100%). There was a significantly increased proportion of suppression of puberty in group 3 (P<0.05). Conclusion : It was necessary to use a higher dose of gonadotropin-releasing hormone agonist to suppress early puberty in girls; however further longitudinal study will be needed for their prognosis of final adult height.

• Proceedings of the PSK Conference
• /
• 2001.04a
• /
• pp.122.3-123
• /
• 2001

• 대한생식의학회:학술대회논문집
• /
• 1995.12a
• /
• pp.51-51
• /
• 1995

• 대한생식의학회:학술대회논문집
• /
• 1995.12a
• /
• pp.55-56
• /
• 1995

• 대한생식의학회:학술대회논문집
• /
• 1995.12a
• /
• pp.71-72
• /
• 1995

• Proceedings of the PSK Conference
• /
• 2000.10a
• /
• pp.165.2-166
• /
• 2000

• Proceedings of the Korean Society of Developmental Biology Conference
• /
• 2001.08a
• /
• pp.7-9
• /
• 2001

• 대한생식의학회:학술대회논문집
• /
• 2002.05a
• /
• pp.65-66
• /
• 2002